Histotripsy is a new cancer treatment for tumors of the liver. But is it only for liver cancer? Who’s a good candidate for it? Surgical oncologist Hop Tran Cao, M.D., shares his insights.
A clinical trial led by James L. Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology, is researching combination immunotherapy for cervical cancer.
GSK5764227 has been granted FDA breakthrough therapy designation, potentially expediting its development as a treatment for relapsed/refractory osteosarcoma.
To start the year right, Fred Hutch scientists, providers and a patient advocate share tips to help readers keep up with the deluge of health…
Members of the Keith Dawson Foundation visited the Fox Chase-Temple University Hospital Bone Marrow Transplant Unit at TUH-Jeanes Campus in late December to share goodies…
SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival outcomes than those…
Outcomes are reported for patients with stage I–IV focal anaplastic Wilms tumor (FAWT) treated in the Children’s Oncology Group (COG) AREN0321 study or enrolled in…
$206,000 over two years for female assistant professors conducting research with a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis, or…
An NDA has been submitted to the FDA seeking the approval of TAR-200 for BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumors.
Cazenovia, New York — January 15, 2025 — NCODA is pleased to announce the appointment of Lucio N. Gordan, MD, to its Board of Directors.…
Highlighting the need for regional collaboration in South Asia, a group of leading oncology scholars is calling for targeted investments and policy reforms to address…
